Literature DB >> 3143396

Increased nerve polyol levels in experimental diabetes and their reversal by Sorbinil.

P H Whiting1, I S Ross.   

Abstract

Sciatic nerve glucose, sorbitol, fructose and myo-inositol levels were measured over a 24-week period in rats made diabetic using a single intraperitoneal injection of streptozotocin at 45 mg kg-1 body weight. In addition, the effect of the aldose reductase inhibitor Sorbinil (Pfizer Ltd) at 25 mg kg-1 day-1 in reversing the accumulation of nerve polyols following 8 weeks of diabetes was investigated. Following induction of diabetes 47, 471 and 456% increases and a 43% decrease in sciatic nerve glucose, sorbitol, fructose and myo-inositol concentrations (mumol g-1 wet weight) respectively, were observed by day 14. Over the remainder of the experimental course untreated diabetic control animals demonstrated relatively consistent elevations in sciatic nerve glucose, sorbitol and fructose. Although a significant, progressive reduction in sciatic nerve myo-inositol to 30% of onset values was observed over the first 84 days of the study, this was followed by a spontaneous partial recovery (31%) over the remainder of the experimental course. However, sciatic nerve myo-inositol levels at the end of the study were still significantly lower than onset values (P less than 0.01). Sorbinil treatment, initiated after 8 weeks of diabetes, and without effect on sciatic nerve glucose levels, normalized sorbitol concentrations following 4, 8, or 12 weeks of treatment but only partially reversed the accumulation of fructose by 368, 161 and 199%, compared to age-matched non-diabetic control values, at the above times, respectively. Mean myo-inositol levels were progressively increased following Sorbinil treatment over the experimental period, although the increase was only significant, compared to results from untreated diabetic animals, at weeks 4 and 16.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3143396      PMCID: PMC2013281     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN: 0007-1021


  8 in total

1.  Phosphoinositide metabolism in rat superior cervical ganglion, vagus and phrenic nerve: effects of electrical stimulation and various blocking agents.

Authors:  G L White; H U Schellhase; J N Hawthorne
Journal:  J Neurochem       Date:  1974-01       Impact factor: 5.372

2.  Abnormal sciatic nerve myo-inositol metabolism in the streptozotocin-diabetic rat: effect of insulin treatment.

Authors:  R S Clements; C R Stockard
Journal:  Diabetes       Date:  1980-03       Impact factor: 9.461

Review 3.  Glucose-induced alterations in nerve metabolism: current perspective on the pathogenesis of diabetic neuropathy and future directions for research and therapy.

Authors:  D A Greene; S Lattimer; J Ulbrecht; P Carroll
Journal:  Diabetes Care       Date:  1985 May-Jun       Impact factor: 19.112

4.  Enzymes of myo-inositol and inositol lipid metabolism in rats with streptozotocin-induced diabetes.

Authors:  P H Whiting; K P Palmano; J N Hawthorne
Journal:  Biochem J       Date:  1979-06-01       Impact factor: 3.857

5.  Selective effects of myo-inositol administration on sciatic and tibial motor nerve conduction parameters in the streptozocin-diabetic rat.

Authors:  D A Greene; R A Lewis; S A Lattimer; M J Brown
Journal:  Diabetes       Date:  1982-07       Impact factor: 9.461

6.  Myo-inositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: the effect of aldose reductase inhibition.

Authors:  K R Gillon; J N Hawthorne; D R Tomlinson
Journal:  Diabetologia       Date:  1983-10       Impact factor: 10.122

7.  Sodium- and energy-dependent uptake of myo-inositol by rabbit peripheral nerve. Competitive inhibition by glucose and lack of an insulin effect.

Authors:  D A Greene; S A Lattimer
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

8.  Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil.

Authors:  D R Tomlinson; R J Moriarty; J H Mayer
Journal:  Diabetes       Date:  1984-05       Impact factor: 9.461

  8 in total
  1 in total

1.  Pharmacokinetics of zopolrestat, a carboxylic acid aldose reductase inhibitor, in normal and diabetic rats.

Authors:  P B Inskeep; A E Reed; R A Ronfeld
Journal:  Pharm Res       Date:  1991-12       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.